[Tumor markers in malignant lymphoma].
The clinical usefulness of tumor markers for malignant lymphoma is thought to be in monitoring the therapeutic effect and as a prognostic factor before treatment. The former include specific biological marker such as soluble interleukin-2 receptor measured by ELISA. The latter are cellular prognostic markers detected by immunohistological and flow cytometric analysis. The cyclin D1 over-expression of mantle cell lymphoma in diffuse large B-cell lymphoma, which should be recommended for myeloablative therapy, is a significantly poor prognostic risk factor.
Banno
Shogo
S
Dept. of Clinical Laboratory Medicine, Nagoya City University Medical School.
Ueda
Ryuzo
R
D014408:Biomarkers, Tumor; D019938:Cyclin D1 / Q000032:analysis; D016903:Drug Monitoring; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007376:Interleukin-2 / Q000097:blood; D008223:Lymphoma / Q000175:diagnosis* / Q000235:genetics; D016393:Lymphoma, B-Cell / Q000175:diagnosis; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis; D011379:Prognosis; D015375:Receptors, Interleukin-2 / Q000097:blood
D014408:Biomarkers, Tumor; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D019938:Cyclin D1